LON:CLIN - Clinigen Group Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 932.50 -25.50 (-2.66 %) (As of 04/19/2019 10:27 AM ET)Previous CloseGBX 958Today's RangeGBX 931.50 - GBX 953.5052-Week RangeGBX 716 - GBX 1,054Volume218,107 shsAverage Volume432,646 shsMarket Capitalization£1.23 billionP/E Ratio46.86Dividend Yield0.62%BetaN/A ProfileDiscussionAnalyst RatingsChartDividendEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom. Receive CLIN News and Ratings via Email Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Delivery Sub-IndustryN/A SectorMedical Current SymbolLON:CLIN Previous Symbol CUSIPN/A CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010Debt Debt-to-Equity Ratio56.71 Current Ratio1.54 Quick Ratio1.32Price-To-Earnings Trailing P/E Ratio46.86 Forward P/E Ratio0.36 P/E GrowthN/A Sales & Book Value Annual Sales£422.30 million Price / Sales2.92 Cash FlowGBX 41.84 per share Price / Cash Flow22.29 Book ValueGBX 343.10 per share Price / Book2.72Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares132,428,000Market Cap£1.23 billion Next Earnings DateN/A OptionableNot Optionable Clinigen Group (LON:CLIN) Frequently Asked Questions What is Clinigen Group's stock symbol? Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN." How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group? Clinigen Group announced a dividend on Wednesday, February 27th. Stockholders of record on Thursday, March 21st will be given a dividend of GBX 1.95 per share on Friday, April 12th. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, March 21st. The official announcement can be viewed at this link. View Clinigen Group's Dividend History. How were Clinigen Group's earnings last quarter? Clinigen Group PLC (LON:CLIN) announced its quarterly earnings data on Tuesday, February, 27th. The company reported $21.20 earnings per share for the quarter, beating analysts' consensus estimates of $20.30 by $0.90. The business earned $167.80 million during the quarter. View Clinigen Group's Earnings History. What price target have analysts set for CLIN? 5 analysts have issued 12-month target prices for Clinigen Group's shares. Their predictions range from GBX 1,160 to GBX 1,640. On average, they expect Clinigen Group's stock price to reach GBX 1,325 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Price Targets for Clinigen Group. What is the consensus analysts' recommendation for Clinigen Group? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clinigen Group. Has Clinigen Group been receiving favorable news coverage? Press coverage about CLIN stock has been trending positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Clinigen Group earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future. Who are some of Clinigen Group's key competitors? Some companies that are related to Clinigen Group include Insulet (PODD), Medidata Solutions (MDSO), Array Biopharma (ARRY), Syneos Health (SYNH), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), ICU Medical (ICUI), Tilray (TLRY), Ascendis Pharma A/S (ASND), Penumbra (PEN), Haemonetics (HAE), United Therapeutics (UTHR), Integra Lifesciences (IART), Globus Medical (GMED) and Healthscope (HSO). What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Application (AAAP), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), Albemarle (ALB), RTI International Metals (RTI), NetApp (NTAP) and StatPro Group (SOG). Who are Clinigen Group's key executives? Clinigen Group's management team includes the folowing people: Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)Mr. Martin Abell, CFO & DirectorMs. Debra Ainge, Chief Operating OfficerMatt Parrish, Head of Investor RelationsMr. David Bryant, Director of Corp. Devel. How do I buy shares of Clinigen Group? Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Clinigen Group's stock price today? One share of CLIN stock can currently be purchased for approximately GBX 932.50. How big of a company is Clinigen Group? Clinigen Group has a market capitalization of £1.23 billion and generates £422.30 million in revenue each year. What is Clinigen Group's official website? The official website for Clinigen Group is http://www.clinigengroup.com/. How can I contact Clinigen Group? Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010. MarketBeat Community Rating for Clinigen Group (LON CLIN)Community Ranking: 3.9 out of 5 ( )Outperform Votes: 372 (Vote Outperform)Underperform Votes: 103 (Vote Underperform)Total Votes: 475MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote "Outperform" if you believe CLIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/19/2019 by MarketBeat.com StaffFeatured Article: What is the QQQ ETF?